Swiss Medtech Start-Up Peripal AG Closes Series A1 Financing Round To Launch Novel Patient Aid Device For Home Dialysis

Published: Jul 26, 2017

Peripal AG was founded by ETH and industry experts and has closed a seed round and a Series A round previously. With strong participation from existing investors including StartAngels and other business angels, the cantonal bank ZKB as well as from new investors, Peripal has now executed its adjacent Series A1 financing round to launch the product(s) in the EU in and the US. “We expect our Peripal System® to facilitate the therapy process and to shorten training times. By making home dialysis easier and safer for patients, we also help to reduce healthcare costs”, says Dr. Sandra Neumann, founder and CEO of Peripal AG.

Peripal AG’s product addresses a key step in home dialysis: the manual connection of dialysis tubings to patients’ catheters. This handling by patients/relatives requires dexterity and car-ries the risk of infection, thereby posing a critical hurdle to home dialysis. Each day, more than 1 million such connections are performed worldwide.

“With the Series A1 financing, we will build up the production, further expand the team, and get ready for the EU launch in 2018. We are very excited to finally see the product in the market”, says Reto Koch, chairman of the board.

Chronic kidney failure increases at a rate of 2-4% annually, driven by age, diabetes, and hy-pertension. With the support of Peripal AG’s patient aid device, more patients can receive their therapy in a home setting as opposed to the hospital, resulting in considerable healthcare cost reductions and, hopefully, improved safety and quality of life.

For more information please visit:

About Peripal AG

Peripal AG is an ETH start-up developing medical devices to facilitate dialysis.

There exist about 3 million dialysis patients worldwide and about 300’000 of these perform their dialysis at home with the so-called peritoneal dialysis. Each one of these patients needs to manually connect a catheter to a dialysis product several times a day. Peripal AG’s patient aid supports such a connection.

Peripal AG is based in Zurich. It develops and commercializes a novel patient connect device for chronic dialysis patients at home. Its vision is to allow more dialysis patients to be treated at home.

Contact, Dr. Sandra Neumann CEO / Founder

For more information please visit:

Back to news